April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Sustained Intraocular Pressure Elevations Due To Intravitreal Injection Of Bevacizumab And Ranibizumab
Author Affiliations & Notes
  • Kirstin L. Tawse
    Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania
  • Sarah J. Wehrli
    Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania
  • Marc H. Levin
    Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania
  • Ali Zaidi
    Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania
  • Maxwell Pisitilli
    Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania
  • Maureen G. Maguire
    Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania
  • Alexander J. Brucker
    Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania
  • Footnotes
    Commercial Relationships  Kirstin L. Tawse, None; Sarah J. Wehrli, None; Marc H. Levin, None; Ali Zaidi, None; Maxwell Pisitilli, None; Maureen G. Maguire, None; Alexander J. Brucker, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4362. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kirstin L. Tawse, Sarah J. Wehrli, Marc H. Levin, Ali Zaidi, Maxwell Pisitilli, Maureen G. Maguire, Alexander J. Brucker; Sustained Intraocular Pressure Elevations Due To Intravitreal Injection Of Bevacizumab And Ranibizumab. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4362.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To report the frequency of delayed ocular hypertension in patients receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents for the treatment of exudative age-related macular degeneration (AMD).

Methods: : The charts of all patients receiving intravitreal ranibizumab and/or bevacizumab for exudative AMD from November 2005 to June 2010 at the Scheie Eye Institute were reviewed. In all patients with a baseline intraocular pressure (IOP) <21mmHg, delayed ocular hypertension was defined as an IOP >= 30mm Hg at a single visit, IOP >= 25mm Hg over 2 or more consecutive visits, or IOP >=25mm Hg with initiation of pressure lowering medication(s). IOP characteristics of injected versus non-injected eyes were then compared using survival analyses, with risk assessed by PHREG.

Results: : 281 patients received intravitreal ranibizumab and/or bevacizumab injections for exudative AMD during the study period. Among those, 347 treated eyes (mean number of anti-VEGF injections +/- SD of 8.222 +/- 7.842) and 200 control eyes of unilaterally injected patients were followed for 2.127 +/- 1.471 and 2.098 +/- 1.397 years, respectively after the first treatment. Four of 347 (1.15%) treated eyes experienced delayed ocular hypertension compared to 3 of 200 (1.50%) control eyes. Three control eyes and four treatment eyes experienced IOP >=25 mmHg on a single visit and were not initiated on pressure lowering therapy and therefore did not meet the criteria for delayed ocular hypertension. Of the treated eyes experiencing delayed ocular hypertension, 2 eyes received lucentis only while 2 eyes received both lucentis and avastin prior to the development of ocular hypertension. No statistically significant risk for delayed ocular hypertension was found in eyes receiving intravitreal anti-VEGF injections (hazard ratio +/- 95% confidence interval = 0.426 +/- 0.100 - 1.821; p = 0.2495). When patients with any baseline IOP including glaucoma patients were included in the analysis, again no statistically significant risk for delayed ocular hypertension was found in eyes receiving intravitreal anti-VEGF injections.

Conclusions: : In contrast to recent small case series, this study found no statistically significant increased risk of delayed ocular hypertension in this large sample of patients receiving intravitreal anti-VEGF agents for exudative AMD.

Keywords: intraocular pressure • injection • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×